Cabozantinib Malate API

Name	Cabozantinib Malate
Chinese name	苹果酸卡博替尼
Cas Number	1140909-48-3
Source	Italy
Qualifications	-/-/-/-/-

The original research was Ipsen Ltd (France), which was approved for the treatment of medullary thyroid cancer in 2013 with European marketing approval. In April 2016, the FDA first approved the drug for the treatment of patients with advanced RCC who had previously received anti-angiogenesis therapy. Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor. It is an anticancer drug that can inhibit multiple targets. The targets that can be inhibited include: MET, VEGFR1/2/3, ROS1, RET, At least 9 AXL, NTRK, KIT, etc., are currently the best targeted drugs for the treatment of cancer. At present, cabozantinib has achieved good therapeutic effects in lung cancer, kidney cancer, liver cancer, medullary thyroid carcinoma and solid tumors. Cabozantinib is known as the most effective drug in targeted drugs because of its wide effectiveness against cancer. "Palm Oil".

Hot Tags: cabozantinib malate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Adapalene API, Valganciclovir Hydrochloride API, Lifitegrast API, Dapoxetine API, Tavaborol API, Celecoxib API

• Previous: Dofelite/Dofelite API
• Next: Benidipine Hydrochloride API